Related Experiment Video
Updated: Jul 14, 2026
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Clopidogrel use with stenting
1Doggrell Biomedical Communications, 14 Quandong Crescent, Nightcliff, NT0810, Australia.
Insights
Clopidogrel pretreatment before coronary stenting reduces adverse events. For drug-eluting stents, continue clopidogrel treatment for at least 24 months to prevent stent thrombosis and myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Clopidogrel is established as beneficial in coronary artery stenting.
- Optimal timing and duration of clopidogrel therapy post-stenting require further clarification.
Discussion:
- A loading dose of clopidogrel (300 mg) 6-24 hours pre-intervention with 1-month maintenance reduced 30-day endpoints compared to maintenance alone.
- No additional benefit of clopidogrel beyond 6 months was observed with bare-metal stents.
- Long-term clopidogrel (≥24 months) significantly reduced death and myocardial infarction in patients with drug-eluting stents.
Key Insights:
- Pre-stenting clopidogrel administration is recommended.
- Duration of clopidogrel therapy should be tailored to stent type: 1 month for bare-metal stents and at least 24 months for drug-eluting stents.
- Extended clopidogrel use in drug-eluting stent recipients mitigates risks of stent thrombosis and ischemic events.
Outlook:
- Further research may refine personalized clopidogrel treatment strategies based on patient risk factors and stent type.
- Investigating novel antiplatelet agents or treatment durations could optimize outcomes in complex coronary stenting scenarios.
- Long-term follow-up studies are crucial to fully understand the risk-benefit profile of extended clopidogrel therapy.
Abstract:
Previous clinical trials have established that clopidogrel is beneficial when used with coronary artery stenting. However, questions remain as to when the clopidogrel treatment should be started and how long treatment should be continued for. In a Clopidogrel Registry, it was shown that when subjects received a loading dose of clopidogrel 300 mg, 6-24 h before the intervention and clopidogrel maintenance for 1 month, the primary end point at 30 days (acute myocardial infarction, all cause death and revascularisation) was lower than in subjects who were just given clopidogrel maintenance. An observational study has shown that there are no additional benefits from continuing to use clopidogrel after 6 months from bare-metal stenting. In contrast, long-term treatment with clopidogrel is beneficial in subjects given drug-eluting stents, when long-term stent thrombosis can be a rare complication. Thus, in subjects given drug-eluting stents, there was an incidence of death and non-fatal myocardial infarction (6-24 months after stenting) of 8.4% without clopidogrel and 2.1% with clopidogrel. These results suggest that clopidogrel pretreatment should be used with stenting, and that with drug-eluting stents, clopidogrel treatment should be continued for at least 24 months.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Coronary Artery Disease V: Interprofessional Care
01:26Peripheral Artery Disease IV: Nursing Management
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...